| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Fas like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; CD 262; CD262; CD262 antigen; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death domain containing receptor for TRAIL/Apo2L; Death receptor 5; DR 5; DR5; Fas like protein precursor; KILLER; KILLER/DR5; OTTHUMP00000123492; OTTHUMP00000123493; p53 regulated DNA damage inducible cell death receptor (killer); p53 regulated DNA damage inducible cell death receptor(killer); TNF related apoptosis inducing ligand receptor 2; TNF related apoptosis inducing ligand receptor 2; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TR10B_HUMAN; TRAIL R2; TRAIL receptor 2; TRAIL-R2; TRAILR2; TRANCER; TRICK2; TRICK2A; TRICK2B; TRICKB; Tumor necrosis factor receptor like protein ZTNFR9; Tumor necrosis factor receptor like protein ZTNFR9; Tumor necrosis factor receptor superfamily member 10b; Tumor necrosis factor receptor superfamily; member 10b; ZTNFR9. |
| Entrez GeneID | 8795 |
| clone | 10H6 |
| WB Predicted band size | Calculated MW: 48 kDa; Observed MW: 40,48 kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant human DR5 protein fragments expressed in E.coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于TNFRSF10B(DR5)抗体的3篇参考文献及其摘要概括：
---
1. **"A novel DR5 monoclonal antibody induces tumor cell apoptosis in a TRAIL-independent manner"**
*作者：Li et al. (2019)*
**摘要**：该研究报道了一种新型抗DR5单克隆抗体，可通过独立于TRAIL配体的机制激活凋亡信号，在多种癌细胞系中诱导 caspase 依赖性凋亡，并抑制异种移植肿瘤生长。
---
2. **"Structural optimization of DR5 agonistic antibodies for enhanced apoptosis in solid tumors"**
*作者：Zhang et al. (2021)*
**摘要**：通过抗体工程技术改造DR5抗体的Fc区域，增强其受体交联能力，显著提升对结直肠癌和肺癌细胞的凋亡诱导效果，为临床开发提供新策略。
---
3. **"Combination therapy with anti-DR5 and chemotherapy synergizes against therapy-resistant breast cancer"**
*作者：Park et al. (2020)*
**摘要**：研究发现抗DR5抗体与紫杉醇联合使用时，可通过抑制抗凋亡蛋白Bcl-2并激活JNK通路，协同增强对化疗耐药乳腺癌细胞的杀伤作用。
---
4. **"DR5-targeted antibody-drug conjugate demonstrates potent antitumor activity in pancreatic cancer models"**
*作者：Smith et al. (2022)*
**摘要**：开发了一种靶向DR5的抗体-药物偶联物(ADC)，在胰腺癌模型中显示出高效特异性杀伤肿瘤细胞的能力，同时减少对正常组织的毒性。
---
这些研究涵盖了抗体机制优化、联合疗法及新型药物形式(如ADC)，反映了TNFRSF10B抗体在癌症治疗中的多样化应用。
TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), also known as death receptor 5 (DR5), is a cell surface receptor that plays a critical role in apoptosis signaling. It binds to ligands like TRAIL (TNF-related apoptosis-inducing ligand), triggering caspase activation and programmed cell death. This pathway is essential for regulating tissue homeostasis and eliminating damaged or malignant cells. Antibodies targeting TNFRSF10B are primarily designed to either agonize or antagonize its activity. Agonistic antibodies mimic TRAIL’s function, promoting apoptosis in cancer cells, making them promising candidates for cancer therapy. Conversely, blocking antibodies may inhibit excessive apoptosis in conditions like autoimmune or inflammatory diseases.
Research on TNFRSF10B antibodies has surged due to their therapeutic potential, particularly in oncology. Many cancers overexpress TNFRSF10B, but resistance mechanisms often limit efficacy. Current antibody-based strategies include monotherapy or combination with chemotherapy/radiotherapy to enhance sensitivity. Some antibodies are engineered for improved stability or reduced immunogenicity, such as fully humanized or Fc-optimized formats. However, challenges like off-target effects, variable tumor response, and systemic toxicity remain under investigation. Beyond therapy, TNFRSF10B antibodies serve as tools to study receptor-ligand interactions, apoptosis mechanisms, and biomarker expression in diseases. Clinical trials continue to explore their safety and efficacy, highlighting their dual role as both therapeutic agents and research reagents.
×
